Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label imatinib therapy in refractory metastatic cancer with KIT mutation or amplification
KCT0003729Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib in cancer, Refractory metastatic cancer, sponsored by Samsung Medical Center. Started Apr 2014; status: completed.
02
Drugs
03
Conditions
cancerRefractory metastatic cancer
Beyond the preview
Go deeper on KCT0003729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003729.